Hi doctor,you once stated for a question's answer "we were all disappointed when two recent promising candidates for new entry inhibitors were dropped from clinical development - one for liver toxicity and the other for lack of clinical efficacy. A third candidate remains in clinical trials, and other new drugs and targets are also in early development."were you talking about gilead and pfizer's entry inhibitor s aplaviroc and maraviroc while the one still in trial is boehringer's vicriviroc? thanks!

I appreciate the chance to clarify that remark. Here's the current status of these three drugs: Aplaviroc has been withdrawn from further development due to liver toxicity; Vicrivoroc had one treatment trial suspended due to clinical underperformance, though other trials with this agent are still underway; and maraviroc trials remain open.